Antiemetic therapy for chemotherapy-induced vomiting: Metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone

Marshall, Glenn M.; Kerr, Stephen J.; Vowels, M. R.; O'Gorman-Hughes, D W; White, Les

doi:10.1016/s0022-3476(89)80354-3

Cited by 28 publications

(26 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Published experience with chlorpromazine for AINV prophylaxis is limited [26,27] yet general pediatric experience with it is extensive. The antiemetic activity of chlorpromazine has not been evaluated in combination with a 5-HT3 antagonist.…”

Section: What Pharmacological Interventions Provide Optimalmentioning

confidence: 99%

“…Four of these were RCTs [14,17,26,38]; one was a prospective descriptive study [16]. Of the RCTs, three were conducted exclusively in children [14,26,38]. Doses ranged from approximately 6 to 24 mg/m 2 /day IV.…”

Section: What Doses Of Antiemetic Agents Are Known To Be Effective Inmentioning

confidence: 99%

“…The recommendation for dexamethasone dosing is based on the most robust, published evidence [14,26,38] in children receiving HEC. Because assignment of a maximum dose would be arbitrary, no maximum dexamethasone dose is recommended in this guideline.…”

Section: What Doses Of Antiemetic Agents Are Known To Be Effective Inmentioning

confidence: 99%

“…Four randomized trials that evaluated the use of metoclopramide to prevent AINV in children were included and support the recommended metoclopramide dose [21,26,39,47]. The recommended dose was associated with a complete rate of vomiting control of 74% (17/23) [21].…”

Section: What Doses Of Antiemetic Agents Are Known To Be Effective Inmentioning

confidence: 99%

See 3 more Smart Citations

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Dupuis

Boodhan

Holdsworth

et al. 2013

Pediatric Blood & Cancer

123

163

View full text Add to dashboard Cite

This guideline provides an approach to the prevention of acute antineoplastic‐induced nausea and vomiting (AINV) in children. It was developed by an international, inter‐professional panel using AGREE and CAN‐IMPLEMENT methods. Evidence‐based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082. © 2013 Wiley Periodicals, Inc.

show abstract

Section: What Pharmacological Interventions Provide Optimalmentioning

confidence: 99%

Section: What Doses Of Antiemetic Agents Are Known To Be Effective Inmentioning

confidence: 99%

Section: What Doses Of Antiemetic Agents Are Known To Be Effective Inmentioning

confidence: 99%

Section: What Doses Of Antiemetic Agents Are Known To Be Effective Inmentioning

confidence: 99%

See 2 more Smart Citations

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Dupuis

Boodhan

Holdsworth

et al. 2013

Pediatric Blood & Cancer

123

163

View full text Add to dashboard Cite

show abstract

“…Corticosteroids are more effective antiemetics in chemotherapyinduced nausea and vomiting (CINV) than chlorpromazine or metoclopramide [3,23]. The combination of a steroid and metoclopramide is more effective than chlorpromazine alone [22]. The combination of ondansetron and dexamethasone was superior to ondansetron alone in controlling emetic episodes in children receiving moderately or highly emetogenic chemotherapy [1].…”

Section: Corticosteroidsmentioning

confidence: 99%

Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009

Jordan¹,

Roila

Molassiotis

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

Only a few studies have been carried out in children on the prevention of chemotherapy-induced nausea and vomiting (CINV). 5-HT 3 receptor antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. Most dose studies are available for the 5-HT 3 receptor antagonists ondansetron and granisetron. The new 5-HT 3 receptor antagonist palonosetron was evaluated in one comparative study so far showing promising activity. Combinations of a 5-HT 3 receptor antagonist and dexamethasone showed increased efficacy with respect to a 5-HT 3 receptor antagonist alone. All paediatric patients receiving chemotherapy of high or moderate emetogenic potential should receive a combination of a 5-HT 3 receptor antagonist and dexamethasone to prevent acute emesis. No studies have specifically evaluated antiemetic drugs in the prevention of chemotherapy-induced delayed and anticipatory emesis in children. The role of the NK1 receptor antagonists in children has to be further investigated, although one small study is published so far, showing promising activity in the prevention of CINV with aprepitant. The new proposed guideline from the Multinational Association of Supportive Care in Cancer and the European Society of Clinical Oncology summarises the updated data from the literature and takes into consideration the existing guidelines.

show abstract

A Survey of Antiemetic Use in Children With Cancer

Hoff

Hockenberry-Eaton²,

Patterson³

et al. 1991

Arch Pediatr Adolesc Med

View full text Add to dashboard Cite

Antiemetic therapy for chemotherapy-induced vomiting: Metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone

Cited by 28 publications

References 15 publications

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009

A Survey of Antiemetic Use in Children With Cancer

Contact Info

Product

Resources

About